ETFS S&P Biotech has been an overweight portfolio allocation and either taking profit now or sticking with the position, whilst the price action remains above the 10-day average, will provide a positive outcome.
The added buying interest in the US biotech sector following the recent announcement from Biogen is helping propel the CURE ETF.
You're not a member! Trial today
